Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial
Crossref DOI link: https://doi.org/10.1186/s12933-017-0615-6
Published Online: 2017-10-12
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Natali, Andrea
Nesti, Lorenzo http://orcid.org/0000-0002-0560-6496
Fabiani, Iacopo
Calogero, Enrico
Di Bello, Vitantonio
Funding for this research was provided by:
Boehringer Ingelheim (NA)